Rosetta Genomics Ltd. (ROSGQ)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Rosetta Genomics Ltd. (ROSGQ) trades at $0.00 with AI Score 48/100 (Grade C). Rosetta Genomics Ltd. is a global genomic diagnostics company leveraging proprietary microRNA technologies and FISH-based assays for various cancer types. Market cap: $593, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for ROSGQ: ROSGQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ROSGQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ROSGQ: the 1 perspectives are evenly split.
How is this calculated? →Rosetta Genomics Ltd. (ROSGQ) Healthcare & Pipeline Overview
Rosetta Genomics Ltd. (ROSGQ) is an Israel-based genomic diagnostics firm specializing in microRNA and FISH technologies for cancer detection and classification. The company offers a portfolio of assays for oncology, urology, and endocrinology, serving medical professionals with specialized diagnostic solutions, though its current operational clarity is impacted by its distressed financial status and OTC listing.
What Is the Investment Thesis for ROSGQ?
Rosetta Genomics Ltd. possesses a foundation in proprietary microRNA and FISH-based diagnostic technologies, offering specialized assays for various cancers, including RosettaGX Cancer Origin and UroVysion. These technologies represent a potential strength in the molecular diagnostics market. However, the company operates under significant financial distress, evidenced by a profit margin of -175.8% and a market capitalization of 593. The 'OTC Other' designation, coupled with an extremely low stock price, indicates substantial risk, including potential delisting and unclear current operations. While the prior development of diagnostic technologies and ongoing collaborations, such as with Meir Medical Center, highlight potential, investors face considerable uncertainty regarding the company's operational status and restructuring efforts. The high Beta of 5.34 suggests extreme volatility, reflecting the inherent risks associated with its current financial and market position.
Based on FMP financials and quantitative analysis
ROSGQ Key Highlights
- Market Capitalization stands at $0.00 billion, reflecting the company's distressed financial state and extremely low valuation.
- Profit Margin is significantly negative at -175.8%, indicating substantial losses relative to revenue and operational challenges.
- Gross Margin is 19.4%, suggesting that while there is some profitability from direct sales, high operating expenses lead to overall unprofitability.
- The company's Beta is 5.34, indicating exceptionally high volatility and sensitivity to market movements compared to the broader market.
- Rosetta Genomics Ltd. operates with 86 employees, focusing on genomic diagnostics leveraging proprietary microRNA technologies and FISH-based assays.
Who Are ROSGQ's Competitors?
ROSGQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| NVTA Invitae Corporation | $0.02 | -35.59% | $5.44M | 50 |
| ICLR ICON Public Limited Company | $170.94 | -1.23% | $13.09B | 50 |
| ME 23andMe Holding Co. | $0.61 | +100.00% | $15.31M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ROSGQ's Key Strengths?
- Proprietary microRNA technologies and a licensing agreement with Max Planck Innovation GmbH.
- Diverse portfolio of specialized genomic diagnostic assays for various cancer types.
- Established collaborative partnership with Meir Medical Center for new classifier development.
- Addresses critical diagnostic needs in oncology, urology, and endocrinology.
What Are ROSGQ's Weaknesses?
- Distressed financial state with a negative profit margin of -175.8% and a 593 market cap.
- Designation as 'OTC Other' indicating significant market and regulatory risks.
- Unclear current operations and product offerings, as noted in existing AI insights.
- Potential for delisting from the OTC market due to financial instability.
What Could Drive ROSGQ Stock Higher?
- Leveraging proprietary microRNA technologies and FISH-based assays to address specific diagnostic needs in oncology and other medical fields.
- Collaborative partnership with Meir Medical Center to develop a microRNA classifier for non-small cell lung cancer patients, potentially opening new market segments.
- Any public announcements or filings detailing restructuring efforts or clarification of current operational status, which could provide greater transparency.
- Increased adoption and market penetration of existing diagnostic assays such as RosettaGX Cancer Origin or UroVysion, driven by clinical utility and market demand.
What Are the Key Risks for ROSGQ?
- Financial-distress signal — its Altman Z-Score of -42.03 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Distressed financial state, characterized by a negative profit margin of -175.8% and a 593 market capitalization, indicating severe operational challenges.
- 'OTC Other' designation and extremely low stock price, which pose significant risks including potential delisting and limited investor transparency.
- Unclear current operations and product offerings, as noted in existing AI insights, creating uncertainty regarding the company's future viability.
- Intense competition within the highly innovative genomic diagnostics market, potentially limiting market share and growth opportunities.
- Regulatory hurdles and compliance challenges associated with diagnostic test development, approval, and commercialization in the healthcare sector.
What Are the Growth Opportunities for ROSGQ?
- **Expansion of RosettaGX Cancer Origin Adoption:** Rosetta Genomics' RosettaGX Cancer Origin assay addresses a critical need in oncology by helping to pinpoint the primary source of metastatic cancer. With the global incidence of cancer continuing to rise, and metastatic disease being a significant challenge, the demand for accurate and timely diagnosis remains high. Expanding the clinical adoption and utilization of this specific assay among oncologists represents a substantial growth opportunity. This involves increasing awareness, demonstrating clinical utility through further studies, and potentially expanding insurance coverage, thereby addressing a market segment focused on improving treatment pathways for complex cancer cases.
- **Development of NSCLC MicroRNA Classifier with Meir Medical Center:** The collaborative partnership with Meir Medical Center to develop a microRNA classifier for non-small cell lung cancer (NSCLC) patients eligible for immuno-oncology therapies presents a significant growth avenue. Immuno-oncology is a rapidly expanding field, and identifying patients most likely to respond to these expensive treatments is crucial for optimizing patient outcomes and healthcare resource allocation. This development could position Rosetta Genomics at the forefront of precision medicine in NSCLC, potentially unlocking a new revenue stream from a high-value diagnostic test within a growing therapeutic area.
- **Increased Adoption of UroVysion for Bladder Carcinoma:** UroVysion, a urine-based FISH assay, serves as an adjunct for initial detection and surveillance of bladder carcinoma. Bladder cancer is a prevalent malignancy, and effective, non-invasive methods for detection and monitoring are highly valued. Increasing the adoption rate of UroVysion among urologists and pathologists, particularly for patients with hematuria or those undergoing post-treatment surveillance, could drive revenue growth. This opportunity relies on demonstrating the assay's clinical efficacy, ease of use, and cost-effectiveness compared to traditional methods, thereby expanding its market penetration in urological diagnostics.
- **Leveraging FISH-Based Prognostic and Predictive Tests:** The company's portfolio includes FISH-based tests like ERG/PTEN for prognostic information in prostate cancer and ALK/ROS1 for predictive insights in late-stage lung cancer. These tests cater to specific, high-need areas where precise patient stratification can significantly impact treatment decisions and outcomes. Enhancing the market presence and clinical integration of these specialized assays, through targeted marketing to oncologists and urologists, and by highlighting their value in personalized treatment planning, offers a clear path for growth. The continued focus on precision oncology supports the increasing demand for such specialized prognostic and predictive tools.
- **Growth in PCR Gene Mutation Analysis Services:** Rosetta Genomics provides PCR gene mutation analysis for a range of cancers, including bladder, lung, colon, and melanoma. As molecular profiling becomes standard in cancer care, the demand for comprehensive gene mutation analysis continues to grow. Expanding the reach and utilization of these PCR-based services, potentially by increasing the panel of mutations tested or by targeting new clinical indications, represents a direct growth opportunity. This involves staying current with emerging genetic biomarkers and offering a robust, reliable service that supports oncologists in making informed treatment decisions based on a patient's specific tumor genetics.
What Opportunities Does ROSGQ Have?
- Development and commercialization of new microRNA classifiers, such as for NSCLC immuno-oncology.
- Increased adoption and expanded clinical utility of existing specialized diagnostic assays.
- Growing global demand for personalized medicine and advanced genomic diagnostics.
- Potential for strategic partnerships or restructuring to stabilize financial position and operations.
What Threats Does ROSGQ Face?
- Intense competition from larger, well-funded diagnostic companies and emerging biotech firms.
- Regulatory hurdles and evolving standards for diagnostic test approvals and reimbursement.
- Technological obsolescence if proprietary technologies do not keep pace with scientific advancements.
- Ongoing financial instability and the risk of bankruptcy or liquidation.
What Are ROSGQ's Competitive Advantages?
- Proprietary microRNA technologies, secured by a licensing agreement with Max Planck Innovation GmbH, provide a unique technological foundation.
- Specialized diagnostic assays like RosettaGX Cancer Origin and RosettaGX Reveal address niche but critical diagnostic challenges in oncology and endocrinology.
- The established portfolio of FISH-based tests (UroVysion, ERG/PTEN, ALK/ROS1) offers validated solutions in specific cancer diagnostics.
- Collaborative partnerships, such as with Meir Medical Center, facilitate the development of new, innovative diagnostic tools and expand intellectual property.
What Does ROSGQ Do?
Rosetta Genomics Ltd., established in 2000 and headquartered in Rehovot, Israel, is a global entity specializing in the field of genomic diagnostics. The company has developed and commercialized a range of diagnostic assays by leveraging its proprietary microRNA technologies. Key offerings in this portfolio include RosettaGX Cancer Origin, designed to identify the primary source of metastatic cancer, and mi-KIDNEY, which aids in classifying kidney tumors from pathological specimens. Additionally, RosettaGX Reveal assists in interpreting indeterminate thyroid fine-needle aspirate results, and the company provides various mi-LUNG diagnostic tests for lung cancer. Beyond its microRNA-based solutions, Rosetta Genomics offers UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay. This assay functions as an adjunct to conventional diagnostic methods, supporting the initial detection of bladder carcinoma in patients with hematuria and facilitating ongoing surveillance for tumor recurrence in previously diagnosed individuals. The company's diagnostic suite further extends to ERG/PTEN, FISH-based tests that provide prognostic information for prostate cancer, and ALK/ROS1, predictive FISH-based tests specifically for late-stage lung cancer patients. Rosetta Genomics also conducts PCR gene mutation analysis for bladder, lung, colon, and melanoma cancers. These diagnostic solutions are utilized by a diverse group of medical professionals, including oncologists, urologists, endocrinologists, and cytopathologists, aiming to enhance patient care. The company maintains a licensing agreement with Max Planck Innovation GmbH for its patented microRNA technologies, covering both diagnostic and research applications. Furthermore, Rosetta Genomics has forged a collaborative partnership with Meir Medical Center to develop a microRNA classifier specifically targeting non-small cell lung cancer patients who are candidates for immuno-oncology therapies.
What Products and Services Does ROSGQ Offer?
- Develops and commercializes genomic diagnostic assays using proprietary microRNA technologies.
- Offers RosettaGX Cancer Origin to identify the primary source of metastatic cancer.
- Provides mi-KIDNEY for classifying kidney tumors from pathological specimens.
- Supplies RosettaGX Reveal for interpreting indeterminate thyroid fine-needle aspirate results.
- Delivers various mi-LUNG diagnostic tests for lung cancer.
- Offers UroVysion, a urine-based FISH assay for bladder carcinoma detection and surveillance.
- Provides ERG/PTEN and ALK/ROS1, FISH-based tests for prostate and late-stage lung cancer, respectively.
- Conducts PCR gene mutation analysis for bladder, lung, colon, and melanoma cancers.
How Does ROSGQ Make Money?
- Generates revenue through the sale and provision of specialized genomic diagnostic testing services to medical professionals.
- Monetizes proprietary microRNA technologies through diagnostic applications and research initiatives, supported by a licensing agreement with Max Planck Innovation GmbH.
- Engages in collaborative partnerships, such as with Meir Medical Center, to develop new diagnostic classifiers, potentially leading to future commercialization and revenue streams.
- Offers a diverse portfolio of tests, including microRNA-based and FISH-based assays, catering to different diagnostic needs across various cancer types.
What Industry Does ROSGQ Operate In?
Rosetta Genomics Ltd. operates within the highly specialized and evolving Medical - Diagnostics & Research industry, a segment of the broader Healthcare sector. This industry is characterized by continuous innovation in molecular diagnostics, driven by the increasing demand for personalized medicine and early disease detection. The market for genomic diagnostics, particularly in oncology, is experiencing growth due to advancements in understanding disease at a molecular level. Rosetta Genomics positions itself by leveraging proprietary microRNA technologies and Fluorescence In Situ Hybridization (FISH) assays to offer specialized diagnostic tests for various cancers, including metastatic, kidney, thyroid, bladder, prostate, and lung cancers. The competitive landscape includes larger diagnostic companies and specialized biotech firms, all vying for market share with novel technologies and comprehensive testing panels. Rosetta Genomics' focus on specific microRNA and FISH applications aims to carve out a niche within this competitive environment, addressing particular diagnostic challenges faced by oncologists, urologists, endocrinologists, and cytopathologists.
Who Are ROSGQ's Key Customers?
- Oncologists, who utilize tests for cancer origin, prognosis, and treatment guidance.
- Urologists, who benefit from assays like UroVysion for bladder carcinoma and ERG/PTEN for prostate cancer.
- Endocrinologists, who use tests such as RosettaGX Reveal for thyroid nodule assessment.
- Cytopathologists, who interpret pathological specimens using the company's diagnostic tools.
- Medical centers and research institutions involved in cancer diagnosis and treatment.
Company Profile
Rosetta Genomics Ltd. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Rehovot, IL. The company is led by CEO Douglas Sites. ROSGQ has traded publicly since 2007.
How Rosetta Genomics Ltd. Is Valued
Rosetta Genomics Ltd. carries a market capitalization of 593, placing it in the micro-cap category. Relative to its peer group, ROSGQ's quantitative score of 48/100 is below the peer average of 64/100.
F-Score 3/9Financial Health
Rosetta Genomics Ltd.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -42.03 places it in the distress zone, a signal of elevated financial risk.
ROSGQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary microRNA technologies and a licensing agreement with Max Planck Innovation GmbH.
- Diverse portfolio of specialized genomic diagnostic assays for various cancer types.
- Established collaborative partnership with Meir Medical Center for new classifier development.
- Addresses critical diagnostic needs in oncology, urology, and endocrinology.
Bear Case
- Distressed financial state with a negative profit margin of -175.8% and a 593 market cap.
- Designation as 'OTC Other' indicating significant market and regulatory risks.
- Unclear current operations and product offerings, as noted in existing AI insights.
- Potential for delisting from the OTC market due to financial instability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
ROSGQ Latest News
No recent news available for ROSGQ.
ROSGQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ROSGQ.
Price Targets
Wall Street price target analysis for ROSGQ.
ROSGQ MoonshotScore
What does this score mean?
The MoonshotScore rates ROSGQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Douglas Sites
Chief Executive Officer
Douglas Sites serves as the Chief Executive Officer of Rosetta Genomics Ltd., overseeing the company's operations and strategic direction. With 86 employees under his management, Mr. Sites is responsible for guiding the company's efforts in genomic diagnostics. Specific details regarding his prior career history, educational background, and tenure before assuming the CEO role are not provided in the available data. His leadership is central to the company's ongoing activities in developing and commercializing diagnostic assays leveraging microRNA and FISH technologies.
Track Record: Under Mr. Sites' leadership, Rosetta Genomics Ltd. has maintained its focus on genomic diagnostics, including proprietary microRNA technologies and FISH-based assays. His tenure has seen the continuation of the company's licensing agreement with Max Planck Innovation GmbH and the establishment of a collaborative partnership with Meir Medical Center. Specific milestones or strategic decisions directly attributable to his individual track record beyond his general leadership of the company's stated operations are not detailed in the provided information.
ROSGQ OTC Market Information
Rosetta Genomics Ltd. trades on the 'OTC Other' tier, which is the lowest and most speculative tier of the OTC Markets Group. Unlike companies listed on major exchanges like the NYSE or NASDAQ, which adhere to strict listing standards regarding financial health, corporate governance, and reporting, 'OTC Other' companies have minimal or no public disclosure requirements. This tier typically includes companies that are distressed, defunct, or have not met the requirements for higher OTC tiers. Investors in 'OTC Other' securities face significantly higher risks due to limited information and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited or unknown public disclosure, leading to a lack of transparency regarding financial health and operations.
- High risk of delisting or cessation of trading due to distressed financial state and minimal regulatory oversight.
- Extremely low liquidity and wide bid-ask spreads, making it difficult to trade shares efficiently.
- Increased susceptibility to fraud and manipulation due to less stringent reporting and oversight.
- Potential for complete loss of investment given the company's distressed status and unclear future operations.
- Verify the company's most recent financial filings, if any, directly from OTC Markets or other sources.
- Investigate any public announcements or news regarding operational status, restructuring, or potential delisting.
- Assess the current product offerings and market viability, given the stated unclarity of operations.
- Evaluate the company's intellectual property and licensing agreements for any ongoing value.
- Understand the current management team's plans for addressing financial distress and operational challenges.
- Consider the potential for reverse stock splits or other corporate actions that could impact share value.
- Consult with a financial advisor experienced in highly speculative OTC securities.
- Possession of proprietary microRNA technologies, indicating a foundation in scientific innovation.
- A licensing agreement with Max Planck Innovation GmbH, suggesting external validation of its technology.
- A collaborative partnership with Meir Medical Center for developing a new microRNA classifier.
- Established in 2000, indicating a history of operations in the genomic diagnostics sector.
Common Questions About ROSGQ (Healthcare)
What are Rosetta Genomics Ltd.'s primary diagnostic technologies and applications?
Rosetta Genomics Ltd. primarily leverages two core diagnostic technologies: proprietary microRNA technologies and Fluorescence In Situ Hybridization (FISH) assays. Its microRNA-based portfolio includes RosettaGX Cancer Origin for identifying the primary source of metastatic cancer, mi-KIDNEY for classifying kidney tumors, RosettaGX Reveal for indeterminate thyroid fine-needle aspirates, and various mi-LUNG tests. The FISH-based assays include UroVysion for bladder carcinoma detection and surveillance, ERG/PTEN for prostate cancer prognostics, and ALK/ROS1 for predictive insights in late-stage lung cancer. Additionally, the company offers PCR gene mutation analysis across bladder, lung, colon, and melanoma cancers, providing a comprehensive suite of tools for specialized cancer diagnostics.
What is the significance of Rosetta Genomics Ltd.'s OTC Other classification for investors?
Rosetta Genomics Ltd.'s 'OTC Other' classification signifies that it trades on the lowest tier of the OTC Markets Group, which carries substantial implications for investors. Companies in this tier typically have minimal or no public disclosure requirements, leading to a significant lack of transparency regarding their financial health and operational status. This classification is often associated with distressed or defunct companies, implying a high risk of illiquidity, wide bid-ask spreads, and extreme price volatility. For investors, this means heightened due diligence is required, and there's a considerable risk of limited information, potential delisting, and even a complete loss of investment due to the company's precarious financial and market position.
How does Rosetta Genomics Ltd. position itself within the competitive genomic diagnostics market?
Rosetta Genomics Ltd. positions itself within the competitive genomic diagnostics market by focusing on specialized, proprietary technologies and assays that address specific diagnostic challenges in oncology, urology, and endocrinology. Its core differentiation stems from its proprietary microRNA technologies, backed by a licensing agreement with Max Planck Innovation GmbH, which enables unique diagnostic solutions like RosettaGX Cancer Origin. The company also utilizes established FISH-based assays and PCR gene mutation analysis to offer a diverse portfolio of tests for various cancers. This specialization allows Rosetta Genomics to target niche areas within the broader molecular diagnostics landscape, catering to specific needs of medical professionals, rather than competing broadly with larger, more diversified diagnostic providers.
What are the key factors to evaluate for ROSGQ?
Rosetta Genomics Ltd. (ROSGQ) holds an AI score of 48/100 (low). Not financial advice.
How frequently does ROSGQ data refresh on this page?
ROSGQ prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ROSGQ's recent stock price performance?
Rosetta Genomics Ltd. (ROSGQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary microRNA technologies and a licensing agreement with Max Planck Innovation GmbH. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ROSGQ overvalued or undervalued right now?
Valuing Rosetta Genomics Ltd. (ROSGQ) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ROSGQ?
Before investing in Rosetta Genomics Ltd. (ROSGQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information regarding CEO's detailed background and track record is limited to what was provided.
- Specific competitor tickers were not provided in the source data.
- The 'Unknown' disclosure status for OTC implies significant information asymmetry.
- The 'unclear current operations' mentioned in the AI Insight is a critical factor influencing several sections.